Vertebrate fetuins are multi-domain plasma-proteins of the cystatin-superfamily. Human fetuin-A is also known as AHSG, α 2 -Heremans-Schmid-glycoprotein. Gene-knockout in mice identified fetuin-A as essential for calcified-matrix-metabolism and bone-mineralization. Fetuin-B deficient mice, on the other hand, are female infertile due to zona pellucida 'hardening' caused by the metalloproteinase ovastacin in unfertilized oocytes. In wildtype mice fetuin-B inhibits the activity of ovastacin thus maintaining oocytes fertilizable. Here we asked, if fetuins affect further proteases as might be expected from their evolutionary relation to single-domain-cystatins, known as proteinase-inhibitors. We show that fetuin-A is not an inhibitor of any tested protease. In stark contrast, the closely related fetuin-B selectively inhibits astacin-metalloproteinases such as meprins and ovastacin, but not astacins of the tolloid-subfamily, nor any other proteinase. The analysis of fetuin-B expressed in various mammalian cell types, insect cells, and truncated fish-fetuin expressed in bacteria, showed that the cystatin-like domains alone are necessary and sufficient for inhibition. This report highlights fetuin-B as a specific antagonist of ovastacin and meprin-metalloproteinases. Control of ovastacin was shown to be indispensable for female fertility. Meprin inhibition, on the other hand, renders fetuin-B a potential key-player in proteolytic networks controlling angiogenesis, immune-defense, extracellular-matrixassembly and general cell-signaling, with implications for inflammation, fibrosis, neurodegenerative disorders and cancer.
Control of proteolysis by specific proteinase inhibitors is a prerequisite for physiological homeostasis in health and disease ranging from fertilization, development, blood clotting and immune defense to cancer, Alzheimer's disease, aging and cell death 1 . We have shown recently that fertilization in mammals is regulated through the inhibition of the astacin metalloproteinase ovastacin by fetuin-B, a hepatic plasma protein [2] [3] [4] .
Ovastacin is expressed in the oocyte 5 and stored in cortical granules beneath the plasma membrane (oolemma) of the unfertilized egg, which is surrounded by an extracellular matrix termed zona pellucida [6] [7] [8] . Sperm penetration triggers the bulk release from cortical granules of ovastacin, which cleaves the zona pellucida protein 2 (ZP2) at a specific site (167LA*DE170) 6 . This limited proteolysis of a major component of the zona pellucida is thought to impair sperm-zona interactions, and causes definitive 'hardening' of the zona pellucida 6, 9, 10 .
Fetuin-A and fetuin-B are paralogous plasma proteins of the cystatin superfamily 11 . Many cystatins have been identified as inhibitors of papain-like cysteine proteinases 12 . Hence, the discovery of fetuin-B as an indispensable nanomolar inhibitor of the metalloproteinase ovastacin was unexpected 2 . However, the recent discovery that the caspase-like cysteine proteinase legumain can be inhibited by cystatins has broadened our understanding of enzyme inhibition in that evolutionary distinct families of proteases can be targeted by the same type of inhibitors 13, 14 . Fetuin-A (FETUA/AHSG), fetuin-B (FETUB), histidine-rich glycoprotein (HRG) and kininogen (KNG) 15 are circulating hepatic glycoproteins containing two (fetuins, HRG) or three (KNG) cystatin-like
Results
Activation and functional properties of ovastacin. The pro-ovastacin zymogen was heterologously expressed in insect cells in order to study the mechanism of zymogen activation. In this expression system, pro-ovastacin undergoes partial proteolysis at its C-terminal non-catalytic domain liberating peptides migrating at about 54 kDa and 46 kDa in reducing SDS-PAGE (# and ## in Fig. 1a ). Edman-degradation of both fragments yielded the sequence 24APSA, representing the predicted N-terminus of pro-ovastacin. Bioinformatic analysis based on the X-ray-crystal structure of pro-astacin 39 had suggested that trypsin-like serine proteinases potentially trigger the maturation of pro-ovastacin in vivo. Hence, we performed activation studies with tissue-type plasminogen activator (t-PA), which is present in oocytes 40 , and with plasmin, which is present in follicular and oviductal fluid 41, 42 .
Treatment of recombinant pro-ovastacin with active plasmin liberated peptides of M r 28 kDa and 31 kDa (* and ** in Fig. 1a ). Edman-sequencing of the 28 kDa cleavage product revealed the sequence 86LLSV representing the predicted amino-terminal sequence for mature ovastacin 39 . MALDI-TOF-TOF mass spectrometry of the 28 kDa* fragment from the SDS-PAGE identified peptides exclusively corresponding to the catalytic domain of ovastacin ( Fig. 1d,e ). In contrast, the 31 kDa fragment (**) contained also a peptide mapping to the C-terminal domain ( Fig. 1d,e ). Plasmin-treated pro-ovastacin cleaved casein in zymography (* in Fig. 1c ). While t-PA alone failed to cleave pro-ovastacin, an equimolar mixture of t-PA and plasminogen cleaved pro-ovastacin better than did plasmin alone ( Fig. 1f ).
Varying protein expression system does not alter inhibitory potency of mouse fetuin-B.
Mammalian fetuin-A and fetuin-B were alternatively expressed in adenovirus transduced COS-7 cells 2 , in plasmid transfected CHO cells and in baculovirus transduced High Five insect cells. Molecular masses of the recombinant fetuins varied according to their degree of N-linked glycosylation. Glycan analysis of the recombinant proteins by lectin blotting demonstrated that COS-7 cell-derived fetuins had complex glycosylation with terminal sialic acid, CHO cell-derived fetuins had complex glycosylation largely devoid of terminal sialylation (cf. Supplementary Fig. S1 ), and High Five insect cell-derived fetuins typically had mannose-terminated N-glycans, with little sialylation. Moreover, fetuin-B was also expressed in CHO lec1 cells, which lack complex and hybrid-type glycosylation and in presence of tunicamycin, which prevents regular glycosylation. All these differences in glycosylation did not alter the inhibitory potency (cf. Supplementary Fig. S2 ). Regardless of the cell lines employed for recombinant expression, fetuin-A did not inhibit ovastacin, while fetuin-B from all cell lines strongly inhibited ovastacin (cf. Supplementary Fig. S2 ). Moreover, bacterially expressed, fish (carp) fetuin-A, truncated behind the two cystatin-like domains had undiminished inhibitory potency.
Fetuin-B, but not fetuin-A inhibits substrate cleavage by mouse ovastacin, human meprin α and β, zebrafish nephrosin and crayfish astacin. Knowing that mammalian fetuin-B was a potent
inhibitor of ovastacin, we tested the inhibitory potential of this plasma protein against other mammalian astacin metalloproteinases. Of these, only meprin α and meprin β (Fig. 2) were inhibited by mouse fetuin-B with similar potency like ovastacin, whereas the BMP-1/tolloid-proteases BMP-1 and TLL-2 were not inhibited ( the other hand, there was potent inhibition of non-mammalian astacins such as zebrafish nephrosin and crayfish astacin ( Table 1 , Fig. 2 ). In contrast to fetuin-B, fetuin-A did not inhibit any of the astacins tested (Table 1 ).
Fetuin-A and fetuin-B do not show any inhibitory effect against other metzincins or proteinases of other mechanistic classes.
To study whether fetuins inhibited further proteinases, we tested metzincin superfamily metalloproteinases ADAM10, MMP-2, MMP-9, MMP-8, MMP-13, serine proteinases chymotrypsin, trypsin, plasmin, tissue-type plasminogen activator, cysteine proteinases papain, cathepsins B, cathepsins S, cathepsins K, legumain, and the aspartate proteinase cathepsins D. None of these enzymes was inhibited by fetuin-A or fetuin-B (Table 1) . A transient inhibition of trypsin activity by fetuin-A and fetuin-B was observed, which vanished after pre-incubation of enzyme and fetuin-A for about 30 min ( Fig. 3a ). As shown in Fig. 3b , serine proteinases like trypsin and plasmin cleave fetuin-A and fetuin-B into large fragments of 65 kDa and 55 kDa. Surprisingly, fetuin-B cleaved by trypsin and chymotrypsin was still active as an ovastacin inhibitor ( Supplementary Fig. S3 ), suggesting that limited proteolysis left intact the tertiary structure required for protease inhibition. Supplementary Fig. S3 demonstrates that on non-reducing SDS-gel electrophoresis trypsin-and chymotrypsin-cleaved fetuin-B indeed migrated as single bands indicating that the molecule remained disulfide-bonded and functionally intact despite proteolytic cleavage.
Cleavage of fetuin-A, but not fetuin-B by astacin metalloproteinases. Next, we analyzed
astacin-mediated proteolysis of fetuin-A and fetuin-B. Astacin (Fig. 4a ), meprin β ( Fig. 4a ) and meprin α 43 readily cleaved the 60 kDa fetuin-A liberating fragments of about 40 kDa within one to 24 hours. An exception was BMP-1, which cleaved only a minute portion of the starting material yielding a fragment of about 50 kDa within 24 hours ( Fig. 4b ). Fetuin-B cleavage products could not be detected upon incubation with astacin proteinases (Fig. 4) . These results confirm that fetuin-A is a substrate of astacin metalloproteinases, while fetuin-B is an inhibitor of astacin, which is not cleaved at the molar ratios of the assay.
Discussion
Cystatins are well established inhibitors of papain-like cysteine proteinases, and therefore it was hypothesized that fetuins should likewise inhibit cysteine proteinases. The fact that plasma kininogens containing three cystatin-like domains indeed inhibited cysteine proteinases 17 supported this hypothesis. Here we showed, however, that neither fetuin-A nor fetuin-B are classical cystatin-like thiol proteinase inhibitors, but that fetuin-A was a substrate, not an inhibitor for proteinases of the major proteinase classes serine, cysteine, aspartate, and metallo. In contrast, fetuin-B strongly and specifically inhibited astacin and meprin type metalloproteinases belonging to the metzincin superfamily, which also comprises MMPs, ADAMs, ADAMTS and other zinc proteinases 44, 45 . Fetuin-A has been identified as an important carrier of calcium phosphate in the context of matrix mineralization 19 and additional roles have been suggested 46, 47 . Fetal bovine serum derived fetuin (now known to contain mainly fetuin-A) readily associated with and inhibited trypsin 48 . However, trypsin activity could be recovered by prolonged incubation and this recovery was impeded by the presence of calcium. Fetuin integrity was not studied at the time. We confirmed transient inhibition of trypsin by recombinant fetuin-A. More importantly, we determined that fetuin-A is readily cleaved by trypsin and chymotrypsin (see Fig. 3 ). We conclude that fetuin-A is a preferred substrate of serine proteinases and was mistaken for an inhibitor in this and similar studies, because fetuin-A is cleaved before synthetic substrate of the proteolysis assay, but the state of fetuin-A itself was not studied. Similarly, fetuin-A turned out to be also a substrate for astacin metalloproteinases (this report) and for matrix metalloproteinases 49 . This might have physiological implications, which are not understood in detail yet. For example, the cleavage of fetuin-A by matrix degrading enzymes could impair extracellular matrix mineralization. Vertebrate fetuins capable of inhibiting zinc metalloproteinases had been discovered also in reptiles and fishes. For example the pit viper (Bothrops jararaca) plasma protein BJ46a was found to inhibit ADAM-like snake venom metalloproteinases 50 , and a carp (Cyprinus carpio) plasma-derived fetuin-like protein inhibited the immune defense-associated astacin-metalloproteinase nephrosin 51, 52 . Sequence alignment suggests that fish fetuin is more similar to mammalian fetuin-A than to fetuin-B, yet our work suggests that is functionally more related to mammalian fetuin-B. We speculate that the functional divergence of fetuins, which is seen in mammals, has evolved later in vertebrate evolution. Further work is needed to clarify this point as altogether three fetuin-like transcripts are found in the e.g. zebrafish genome, two of which are fetuin-B like 15 .
The inhibition of the metalloproteinase ovastacin by fetuin-B was the first observation of an astacin-like zinc-proteinase being antagonized by a member of the cystatin protein superfamily in mammals 2 . Pro-ovastacin is proteolytically inactive and requires removal of an amino-terminal pro-peptide to gain activity. Additionally, there is trimming at the C-terminal end. This report provides evidence for the activation of pro-ovastacin by a proteinase with trypsin-like cleavage specificity. In mouse oocytes two forms of ovastacin were detected in vivo, the 44 kDa pro-ovastacin and the mature ovastacin of 29 kDa, which is produced intracellularly by a hitherto unidentified proteinase 4 . Recombinant 46 kDa pro-ovastacin expressed in insect cells was processed by plasmin in vitro, liberating a catalytically active 28 kDa fragment that was identified by N-terminal sequencing and mass spectrometry to contain positions 86LLSV-to-NCSR283 of the complete ovastacin sequence (see Fig. 1 ). This variant likely corresponds to the 29 kDa form observed in mouse oocytes. The additional 31 kDa form is only partially processed on the C-terminal side and carries an elongation of 26 residues as determined by mass spectrometry. Minor differences in molecular masses (46 kDa vs. 44 kDa or 29 kDa vs. 28 kDa) are probably due to alternative modifications in mouse compared to insect cells.
The observation that pro-ovastacin can be activated by trypsin-activated plasmin and even better by a combination of plasmin and the trypsin-like proteinase t-PA, suggest thats a finely tuned proteolytic network controls the fertility of oocytes. This proteolytic network likely involves trypsin-like serine proteinases, which mediate ovastacin processing, active ovastacin, which cleaves the zona pellucida protein ZP2 thereby mediating definitive zona pellucida hardening, and fetuin-B, which regulates ovastacin activity 2, 4, 53, 54 . Trypsin-like proteinases such as the tissue-type plasminogen activator (t-PA) exist in oocyte cortical granules 40 , and plasminogen exists in the follicular and oviductal fluids 41, 42 . Both proteinases could be involved in a step-wise activation of pro-ovastacin. The observation that t-PA, which is secreted from oocytes 40 , on its own was not capable of activating ovastacin, whereas the combination of t-PA and plasminogen proved more effective than trypsin-activated plasmin alone, suggests that the partial intracellular activation of pro-ovastacin 4 is mediated by a hitherto unidentified tryptic activity possibly present in cortical granules. Candidate serine proteinases were identified by proteomic analysis of the oocyte secretome 55 .
Changing expression systems did not alter inhibitory potency of fetuin-B. Bacterially expressed fish fetuin, truncated after the two cystatin-like domains, has inhibitory potency against astacin proteinases. This indicated that the presence of the C-terminal domain, glycosylation or other eukaryotic posttranslational modifications did not contribute essentially to function. This is in line with unchanged functional properties in fetuins expressed in High five insect cells, and mammalian COS-7 and CHO cells, respectively. Collectively, these results suggest that the cystatin-like protein domains are necessary and sufficient for the inhibitory function of fetuin-B.
Mouse ovastacin, human meprin α and β, zebrafish nephrosin and crayfish astacin are effectively inhibited by mouse fetuin-B. The only astacin proteinases resistant to fetuin-B inhibition were the members of the BMP-1/ tolloid subfamily. As shown by crystal structure analysis 56 and mass spectrometry 57 , these enzymes have in common a unique vicinal disulfide bond located in the substrate binding β-strand in intimate distance to the zinc ion of the active site. This arrangement most likely prevents access of fetuin-B to the active site.
Mouse fetuin-A did not show inhibitory activity against any of the enzymes tested. Hence, the inhibitory effect seems restricted to fetuin-B only. This seemingly contradicts our previous statement that fetuin-A can inhibit meprin proteinases 43 . We know now that commercial fetuin preparations contain mostly fetuin-A, but also sufficient fetuin-B to explain the observed inhibition given the strong inhibitory activity of fetuin-B 2 . Consequently, commercial antibodies against (contaminated) fetuin-A inevitably cross-reacted with fetuin-B and neutralized both proteins as observed 53 .
Interestingly, fetuin-A may influence metalloproteinase activity nevertheless explaining reports of fetuin-MMP interaction. In the present study we noticed an enhancing/stabilizing effect of fetuin-A in its interaction with ovastacin (see Supplementary Fig. 2a; and ref. 2 ) and also for meprin α and β (data not shown). Similarly, protease stabilization by fetuin was reported for other metzincin proteinases such as pro-MMP-3 and (pro-) MMP-9 [58] [59] [60] . Together, these observations suggest a supporting, scaffolding role for fetuin-A.
Fetuin-A and fetuin-B do not show any inhibitory effect against other metzincins or proteinases of other mechanistic classes. Regarding mammalian astacins, the inhibitory effect of fetuin-B was only observed against ovastacin and meprins. Beyond, other targets were fish nephrosin and the prototypical crayfish astacin. However, other metzincin metalloproteinases such as MMP-2, MMP-9, MMP-13, ADAM10 are most likely not physiological targets of fetuin-B, since they were not inhibited. Other proteinases not antagonized by fetuins are cysteine cathepsins-B, -K, -S and papain, the aspartate proteinase cathepsins-D, serine proteinases like trypsin, chymotrypsin or plasmin. A special case is the caspase-like cysteine proteinase legumain, which has been shown to be inhibited by cystatin-C-like members of the cystatin superfamily 14 , but -surprisingly -not with the N-terminus and two hairpin-loops as in the classic interaction with papain-like cysteine proteinases, but rather with a unique legumain-specific reactive site observed biochemically earlier by Abrahamson and coworkers 61 . We checked legumain for inhibition by fetuin-B and did not observe any effect, which is consistent with the absence of the typical asparaginyl-loop exposed by cystatin-C and -D for inhibition of legumain-like enzymes ( Table 1 ).
In conclusion, fetuin-B emerges as a novel mammalian plasma proteinase inhibitor, selectively targeting members of the astacin-family of zinc metalloproteinases, namely ovastacin, meprin α and meprin β. While the SCIEnTIfIC REPORtS | (2019) 9:546 | DOI:10.1038/s41598-018-37024-5 regulated inhibition of ovastacin by fetuin-B has been shown to be essential and indispensable for female fertility, the consequences of meprin inhibition are less well understood, but could potentially affect many physiological functions. Meprins are pivotal in proteolytic networks controlling angiogenesis, immune defense, extracellular matrix assembly and general cell signaling, which might implicate consequences for inflammation, fibrosis, neurodegenerative disorders and cancer 25, [27] [28] [29] [30] [31] [32] [33] [36] [37] [38] .
Methods
Enzymes and substrates were prepared as described below or obtained from commercial sources as listed in Table 2 .
Recombinant Enzymes. Recombinant mouse pro-ovastacin (Q6HA09) 2 , human meprin α (Q16819) 62 , human meprin β (Q16820) 63 , hBMP-1 (P13497) 64 , Astacus astacus astacin (P07584) 65 and human MMP-9 (P14780) 66 (a kind gift of Ghislain Opdenakker, Leuwen, Belgium) were prepared as described. For proteolytic activation, pro-ovastacin was mixed with human or murine plasmin in a molar ratio of 10:1 in 50 mM Tris/HCl pH 7.4, 150 mM NaCl buffer and incubated for 30 min at 37 °C before addition of 10 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF/Pefabloc ® , Sigma-Aldrich, Taufkirchen, Germany) and incubation for another 10 min. Under the same conditions pro-ovastacin was activated with trypsin (300:1), t-PA (6:1) or a combination of plasminogen and t-PA (10:1:1). Activation was verified in an activity assay using fluorogenic substrates ( Table 2 ). The activation by plasmin was confirmed by casein zymography performed under non-reducing conditions. The plasmid encoding the proteinase domain of human TLL-2 (Q9Y6L7), TLL-2 cat was a gift of the Novartis Institute for Biomedical Research (Basel, Switzerland). TLL-2 was expressed in E. coli 56 renatured from inclusion bodies 67 , purified by gelfiltration and dialyzed against 50 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM CaCl 2 , 0.02% octyl-β-D-glucopyranoside for further use. Recombinant C-terminally Strep-tagged Danio rerio nephrosin (Gene ID: 404039) was expressed in insect cells using the protocol developed for meprin 62, 63 . Nephrosin was concentrated by ammonium sulfate precipitation and purified via Strep-tactin affinity chromatography as published for meprin α 62,63 . Electrophoresis. SDS-PAGE was set up according to ref. 68 . For zymography, 0.1% casein (Hammarsten grade, Sigma-Aldrich, Taufkirchen, Germany) was added to the separation gel. All other buffers were prepared as described 69 Western blotting and glycoanalysis. For immunoblotting the separated proteins were transferred to polyvinylidene difluoride (PVDF)-membrane (Immobilon ® FL, MerckMillipore, Darmstadt, Germany) via semi-dry blotting 70 at constant 20 V for 30-60 min. Immunodetection of fetuin fragments was performed with rabbit anti-mouse fetuin-A and rabbit anti-mouse fetuin-B antibodies 2 or with anti-His-tag antibodies (Qiagen, Hilden, Germany; 1:2000 in 1% BSA TBS-T). For glycoanalysis proteins were blotted onto a nitrocellulose membrane (Sigma-Aldrich, Taufkirchen, Germany, Germany) using a semi-dry blotting device (BioRad, München, Germany). The membrane was blocked with 2,5% BSA powder in PBS-T (PBS supplemented with 0.05% Tween-20, Applichem, Darmstadt, Germany) for 1 h at 37 °C. Blotted proteins were probed with lectins (Vector Laboratories, Burlingame, USA) from Sambucus nigra (EBL,), Erythrina cristagalli (ECL), Griffonia simplicifolia (GS-II) for terminal sialic acid, galactose and N-Acetylglucosamin respectively. Lectins were diluted 1:2000 in PBS-T and applied for 1 h at 37 °C. Streptavidin-POD conjugate (Streptavidin covalently coupled to horseradish peroxidase, Sigma) was diluted 1:5000 in PBS-T and incubated for 1 h at 37 °C. Afterwards, membranes were washed three times with PBS-T for 5 min. Conjugate bound to lectins was detected by chemiluminescence in substrate solution (0.1 M Tris/HCl, pH 8.5, 1.25 mM 3-aminopthalhydrazide, 0.45 mM p-coumaric acid, 0.015% hydrogen peroxide) using the fluorescence imager Fuji LAS Mini 4000 (GE Healthcare, Freiburg, Germany).
Fetuins. Bovine
Enzymatic assays and determination of kinetic constants. Kinetics of substrate hydrolysis was monitored in a temperature-controlled Varioskan Flash 3001 spectral plate reader equipped with the SkanIt Software 2.4.3.RE (Thermo Scientific, Dreieich, Germany) in a total volume of 100 µl at 37 °C. The reactions were started by addition of substrate and initial velocities were recorded for at least 360 s (>70 times for 100 ms at intervals of 5 s). Thereafter, in the case of quenched fluorescent substrates, 20 µg of concentrated proteinase in 1 µl buffer to cleave all remaining substrate, and the reaction was monitored for another 15 min. For calculation of the rate of substrate turnover the following formula was used: v = [S]*m/ΔF, m [F/t]: slope of initial substrate turnover; ∆F: maximum fluorescence intensity after complete substrate turnover, [S]: substrate concentration. Enzymes and substrates are listed in Table 2 . Kinetic parameters were analyzed using GraFit 4 (Erithacus Software, Wilmington House, UK); K i values were calculated using the equation published by Joseph Bieth 71 .
In activity or inhibition assays ovastacin was used at concentrations in the range of 0.018-5 µM. Fetuin-A and fetuin-B were tested at concentrations of 0.4 nM-1.2 µM. Enzyme activity measurements were started by addition of 10-32 µM Ac-RE(Edans)-DR-Nle-VGDDPY-K(Dabcyl)-NH 2 dissolved in 0.4% DMSO (dimethyl sulfoxide).
Crayfish astacin 65 was assayed after pre-incubation for 10 minutes at 37 °C with fetuin-A (0.25 nM-2 µM, 10 nM enzyme) or fetuin-B (0.2 nM-0.9 µM, 1 nM enzyme), before addition 14 µM Mca-GSPAFLA-K(Dnp)-dR-NH 2 in 0.5% DMSO or 0.4 mM Dns-PKRAPWV substrate both in 50 mM Hepes pH 8.0. TLL-2 (180 or 250 nM) and BMP-1 (10 nM) were pre-incubated for 10 min at 37 °C with fetuin-A or fetuin-B (0.005 nM-3 µM). The reaction in 50 mM Hepes, pH 7.2, 150 mM NaCl, 5 mM CaCl 2 , 0.04% SCIEnTIfIC REPORtS | (2019) 9:546 | DOI:10.1038/s41598-018-37024-5 N-terminal sequencing and mass spectrometry. Human plasmin activated pro-ovastacin was submitted to SDS-PAGE and immunoblotting onto PVDF membrane. N-terminal sequence of the resulting 28 kDa band was determined via Edman-degradation 72 by ChromaTec GmbH (Greifswald, Germany), who also identification other cleavage products, in gel bands by Maldi-TOF-TOF analysis.
